Statins in combinations: From ARBITER-6 HALTS to ACCORD-what works?

Current Atherosclerosis Reports

Volumn 13, Issue 1, 2011, Pages 4-8

  Clearfield, Michael ^a  

^a Touro University California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; EZETIMIBE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB;

ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED DRUG RELEASE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG MECHANISM; HIGH RISK POPULATION; HUMAN; INTRAVASCULAR ULTRASOUND; LONG TERM CARE; METABOLIC SYNDROME X; NOTE; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PROSPECTIVE STUDY; TREATMENT DURATION;

EID: 79551531732     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0142-3     Document Type: Note

References (25)

1. Cholesterol Treatment Trialists Collaboration 2005 Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins Lancet 366 1267 1278 10.1016/S0140-6736(05)67394-1 (Pubitemid 41416582)
2. PL Canner KG Berge NK Wenger, et al. 1986 Fifteen year mortality in Coronary Drug Project patients: Long term benefit with niacin J Am Coll Cardiol 8 1245 1255 1:STN:280:DyaL2s%2FlvVCqtQ%3D%3D 10.1016/S0735-1097(86)80293-5 3782631
3. The Lipid Research Clinics coronary primary prevention trial results. Reduction in incidence of coronary heart disease. (LRC-CPPT) JAMA 1984;251:351-364.
4. D Ornish SE Brown LW Scherwitz, et al. 1990 Can lifestyle changes reverse coronary heart disease? Lancet 336 129 133 1:STN:280:DyaK3czhvVWmug%3D%3D 10.1016/0140-6736(90)91656-U 1973470 (Pubitemid 20224971)
5. H Buchwald RL Varco JP Matts, et al. 1990 Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report on the Program on the Surgical Control of Hyperlipidemia (POSCH) N Engl J Med 323 946 955 1:STN:280:DyaK3czosVGiuw%3D%3D 10.1056/NEJM199010043231404 2205799
6. PM Ridker E Danielson F Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2197 2207 10.1056/NEJMoa0807646
7. CP Cannon E Braunwald MCabe, et al. 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndrome N Engl J Med 350 1495 1504 1:CAS:528:DC%2BD2cXjtVeqtr8%3D 10.1056/NEJMoa040583 15007110 (Pubitemid 38477774)
8. BG Brown JJ Albers LF Fisher, et al. 1990 Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1289 1298 1:STN:280:DyaK3M%2FhsFaksw%3D%3D 10.1056/NEJM199011083231901 2215615
9. JJ Kastelein F Akdim E Stroes, et al. 2008 Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 1431 1443 1:CAS:528:DC%2BD1cXkt12qt7c%3D 10.1056/NEJMoa0800742 18376000 (Pubitemid 351482735)
10. JL Fleg M Mete BV Howard, et al. 2008 Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes. The SANDS Trial J Am Coll Cardiol 52 2198 2205 1:CAS:528:DC%2BD1cXhsFajs7rJ 10.1016/j.jacc.2008.10.031 19095139
11. BG Brown XQ Zhao A Chait, et al. 2001 Simvastatin and niacin, antioxidant vitamins or the combination for the prevention or coronary artery disease N Engl J Med 345 1583 1592 1:CAS:528:DC%2BD3MXoslyhsLs%3D 10.1056/NEJMoa011090 11757504 (Pubitemid 33126837)
12. D Bassler M Briel Vm Montori, et al. 2010 STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis JAMA 303 1180 1187 1:CAS:528:DC%2BC3cXktVWiu70%3D 10.1001/jama.2010.310 20332404
13. AJ Taylor LE Sullenberger HJ Lee, et al. 2004 Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER 2) Circulation 110 3512 3517 1:CAS:528:DC%2BD2MXhtVGnt7s%3D 10.1161/01.CIR. 0000148955.19792.8D 15537681 (Pubitemid 39612564)
14. PW Wilson KM Anderson WP Castelli 1991 Twelve year incidence coronary heart disease in middle aged adults during the era of hypertensive therapy. Framingham Offspring Study Am J Med 90 11 16 1:STN:280:DyaK3M%2Fps1yisg%3D%3D 10.1016/0002-9343(91)90500-W 1986576
15. DJ Gordon BM Rifkind 1989 High density lipoprotein-the clinical implications of recent studies N Engl J Med 321 1311 1316 1:STN:280: DyaK3c%2FhsFSmsA%3D%3D 10.1056/NEJM198911093211907 2677733
16. L Mosca LJ Appel EJ Benjamin, et al. 2004 Evidence based guidelines for cardiovascular disease prevention in women Circulation 109 672 693 10.1161/01.CIR.0000114834.85476.81 14761900 (Pubitemid 38198877)
17. M Clearfield 2008 Clinical Trial Reports: Torcetrapib and the progression of coronary atherosclerosis Curr Atheroscler Reports 10 7 10
18. SM Grundy JI Cleeman CN Mertz, et al. 2004 National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516 (Pubitemid 38924592)
19. BG Brown KH Stukovsky XQ Zhao 2006 Simultaneous LDL-C lowering and HDL-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized trials Curr Opin Lipidol 17 631 636 1:CAS:528:DC%2BD28XhtFymtLzN 10.1097/MOL. 0b013e32800ff750 17095907 (Pubitemid 44729955)
20. Duivenvoorden DS, Gorbbee DE, Kastelein JJ et al.: Ultrasound protocols to measure carotid intima -media thickness in trials; comparison of reproducibility, rate of progression and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med 2010;
21. Blumenthal RS, Michos ED. The HALTS Trial-Halting atherosclerosis or halted too early? N Engl J Med 2009;
22. XQ Zhao RA Krasuski J Baer, et al. 2009 Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: A combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS) and the Armed Forces Regression Study (AFREGS) Am J Cardiol 104 1457 1464 1:CAS:528:DC%2BD1MXhsVGlt7zO 10.1016/j.amjcard.2009.07.035 19932775
23. SE Nissen SJ Nicholls Sipahi, et al. 2006 Effect of very high intensity statin therapy on regression of coronary atherosclerosis JAMA 295 1556 1565 1:CAS:528:DC%2BD28Xjt12itrc%3D 10.1001/jama.295.13.jpc60002 16533939
24. SJ Nicholls EM Tuzcu I Sipahi, et al. 2007 Statins, HDL-C and regression of coronary atherosclerosis JAMA 297 499 508 1:CAS:528:DC%2BD2sXhs1Wis7k%3D 10.1001/jama.297.5.499 17284700 (Pubitemid 46220805)
25. RM Califf Y Lokhnugina CP Cannon, et al. 2010 An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) Am Heart J 159 705 709 10.1016/j.ahj.2010.03.004 20435175